PICO Portalanswers from OpenAlex
JCO Precision Oncology
JournalCitation impact & published research
JCO Precision Oncology is a journal indexed in PICO Portal from OpenAlex.
How many works does JCO Precision Oncology have?
PICO Portalindexed works
JCO Precision Oncology has 2,077 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does JCO Precision Oncology have?
PICO Portalcitation count
JCO Precision Oncology has 36,979 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of JCO Precision Oncology?
PICO Portalh-index
JCO Precision Oncology has an h-index of 75 in OpenAlex.
What is the OpenAlex record for JCO Precision Oncology?
PICO Portalopenalex
The OpenAlex for JCO Precision Oncology is on the source record.
What are the most-cited papers on JCO Precision Oncology?
PICO Portalmost cited works
OncoKB: A Precision Oncology Knowledge Base
Debyani Chakravarty, Jianjiong Gao, Sarah Phillips, Ritika Kundra, Hongxin Zhang, Jiaojiao Wang, Julia E. Rudolph, Rona Yaeger, Tara E. Soumerai, Moriah H. Nissan, Matthew T. Chang, Sarat Chandarlapaty, Tiffany A. Traina, Paul K. Paik, Alan L. Ho, Feras Hantash, Andrew Grupe, Shrujal S. Baxi, Margaret K. Callahan, Alexandra Snyder, Ping Chi, Daniel C. Danila, Mrinal M. Gounder, James J. Harding, Matthew D. Hellmann, Gopa Iyer, Yelena Y. Janjigian, Thomas Kaley, Douglas A. Levine, Maeve A. Lowery, Antonio Omuro, Michael A. Postow, Dana E. Rathkopf, Alexander N. Shoushtari, Neerav Shukla, Martin H. Voss, Ederlinda Paraiso, Ahmet Zehir, Michael F. Berger, Barry S. Taylor, Leonard B. Saltz, Gregory J. Riely, Marc Ladanyi, David M. Hyman, José Baselga, Paul Sabbatini, David B. Solit, Nikolaus Schultz
Analysis of <i>NTRK</i> Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics
Ryosuke Okamura, Amélie Boichard, Shumei Kato, Jason K. Sicklick, Lyudmila Bazhenova, Razelle Kurzrock
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Non–Small-Cell Lung Cancer
Justin F. Gainor, Diane Tseng, Satoshi Yoda, Ibiayi Dagogo‐Jack, Luc Friboulet, W. Marston Linehan, Harper Hubbeling, Leila Dardaei, Anna F. Farago, Katherine R. Schultz, Lorin A. Ferris, Zofia Piotrowska, James C.H. Hardwick, Donghui Huang, Mari Mino–Kenudson, A. John Iafrate, Aaron N. Hata, Beow Y. Yeap, Alice T. Shaw
Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic Model
Nathan A. Pennell, Alex Mutebi, Zheng‐Yi Zhou, Marie Louise Ricculli, Wenxi Tang, Helen Wang, Annie Guérin, Tom Arnhart, Anand A. Dalal, Medha Sasané, Kevin Y. Wu, Kenneth W. Culver, Gregory A. Otterson
Clinicopathologic Features of Non–Small-Cell Lung Cancer Harboring an <i>NTRK</i> Gene Fusion
Anna F. Farago, Martin S. Taylor, Robert C. Doebele, Viola W. Zhu, Shivaani Kummar, Alexander I. Spira, Theresa A. Boyle, Eric B. Haura, Maria E. Arcila, Ryma Benayed, Dara L. Aisner, Nora Horick, Jochen K. Lennerz, Long P. Le, A. John Iafrate, Sai‐Hong Ignatius Ou, Alice T. Shaw, Mari Mino–Kenudson, Alexander Drilon